<table id="table16" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 16. Mean Pharmacokinetic Parameters in Pediatric Subjects with Epilepsy</caption>
<col align="left" valign="top" width="31%"></col>
<col align="center" valign="top" width="15%"></col>
<col align="center" valign="top" width="17%"></col>
<col align="center" valign="top" width="17%"></col>
<col align="center" valign="top" width="20%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule">Pediatric Study Population</th>
<th stylecode="Rrule">Number of Subjects</th>
<th stylecode="Rrule">T<sub>max</sub> (h)</th>
<th stylecode="Rrule">t<sub>½</sub> (h)</th>
<th stylecode="Rrule">CL/F (mL/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Ages 10 months-5.3 years</content>
</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
</tr>
<tr>
<td stylecode="Lrule Rrule">  Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone<footnote id="table16a">Carbamazepine, phenytoin, phenobarbital, and primidone have been shown to increase the apparent clearance of lamotrigine. Estrogen-containing oral contraceptives, rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir have also been shown to increase the apparent clearance of lamotrigine <content stylecode="italics">[see <linkhtml href="#S7">Drug Interactions (7)</linkhtml>]</content>.</footnote>
</td>
<td stylecode="Rrule" valign="middle">10</td>
<td stylecode="Rrule" valign="bottom">3.0<br/>(1.0-5.9)</td>
<td stylecode="Rrule" valign="bottom">7.7<br/>(5.7-11.4)</td>
<td stylecode="Rrule" valign="bottom">3.62<br/>(2.44-5.28)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">  Subjects taking antiepileptic drugs with no known effect on the apparent clearance of lamotrigine</td>
<td stylecode="Rrule" valign="middle">7</td>
<td stylecode="Rrule" valign="bottom">5.2<br/>(2.9-6.1)</td>
<td stylecode="Rrule" valign="bottom">19.0<br/>(12.9-27.1)</td>
<td stylecode="Rrule" valign="bottom">1.2<br/>(0.75-2.42)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  Subjects taking valproate only</td>
<td stylecode="Rrule">8</td>
<td stylecode="Rrule">2.9<br/>(1.0-6.0)</td>
<td stylecode="Rrule">44.9<br/>(29.5-52.5)</td>
<td stylecode="Rrule">0.47<br/>(0.23-0.77)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Ages 5-11 years</content>
</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
</tr>
<tr>
<td stylecode="Lrule Rrule">  Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone<footnoteref idref="table16a"></footnoteref>
</td>
<td stylecode="Rrule" valign="middle">7</td>
<td stylecode="Rrule" valign="bottom">1.6<br/>(1.0-3.0)</td>
<td stylecode="Rrule" valign="bottom">7.0<br/>(3.8-9.8)</td>
<td stylecode="Rrule" valign="bottom">2.54<br/>(1.35-5.58)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">  Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone<footnoteref idref="table16a"></footnoteref> plus valproate</td>
<td stylecode="Rrule" valign="middle">8</td>
<td stylecode="Rrule" valign="bottom">3.3<br/>(1.0-6.4)</td>
<td stylecode="Rrule" valign="bottom">19.1<br/>(7.0-31.2)</td>
<td stylecode="Rrule" valign="bottom">0.89<br/>(0.39-1.93)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  Subjects taking valproate only<footnote>Two subjects were included in the calculation for mean T<sub>max</sub>.</footnote>
</td>
<td stylecode="Rrule">3</td>
<td stylecode="Rrule">4.5<br/>(3.0-6.0)</td>
<td stylecode="Rrule">65.8<br/>(50.7-73.7)</td>
<td stylecode="Rrule">0.24<br/>(0.21-0.26)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Ages 13-18 years</content>
</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
</tr>
<tr>
<td stylecode="Lrule Rrule">  Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone<footnoteref idref="table16a"></footnoteref>
</td>
<td stylecode="Rrule" valign="middle">11</td>
<td stylecode="Rrule" valign="middle">___<footnote id="table16c">Parameter not estimated.</footnote>
</td>
<td stylecode="Rrule" valign="middle">																___<footnoteref idref="table16c"></footnoteref>
</td>
<td stylecode="Rrule" valign="middle">1.3</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">  Subjects taking carbamazepine, phenytoin, phenobarbital, or primidone<footnoteref idref="table16a"></footnoteref> plus valproate</td>
<td stylecode="Rrule" valign="middle">8</td>
<td stylecode="Rrule" valign="middle">																___<footnoteref idref="table16c"></footnoteref>
</td>
<td stylecode="Rrule" valign="middle">																___<footnoteref idref="table16c"></footnoteref>
</td>
<td stylecode="Rrule" valign="middle">0.5</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">  Subjects taking valproate only</td>
<td stylecode="Rrule" valign="middle">4</td>
<td stylecode="Rrule" valign="middle">																___<footnoteref idref="table16c"></footnoteref>
</td>
<td stylecode="Rrule" valign="middle">																___<footnoteref idref="table16c"></footnoteref>
</td>
<td stylecode="Rrule" valign="middle">0.3</td>
</tr>
</tbody>
</table>